AI assistant
Sending…
Werewolf Therapeutics, Inc. — Director's Dealing 2021
May 4, 2021
34192_dirs_2021-05-04_07ace112-a081-4cf6-89c6-97de823e5ee3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Werewolf Therapeutics, Inc. (HOWL)
CIK: 0001785530
Period of Report: 2020-12-08
Reporting Person: HICKLIN DANIEL J (Director, See Remarks, 10% Owner)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-12-08 | Stock Option (right to buy) | $4.77 | A | 727377 | Acquired | 2030-12-07 | Common Stock (727377) | Direct |
| 2021-04-30 | Stock Option (right to buy) | $16.00 | A | 155416 | Acquired | 2031-04-29 | Common Stock (155416) | Direct |
Footnotes
F1: The option was granted on December 8, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the grant date and 2.0833% of the shares vesting each month thereafter through December 8, 2024.
F2: The option was granted on April 30, 2021. The shares underlying the option vest over four years in equal monthly installments through April 30, 2025.
More from Werewolf Therapeutics, Inc.
Annual Report
2026
Mar 27
Regulatory Filings
2026
Mar 27
Regulatory Filings
2026
Feb 24
Regulatory Filings
2026
Feb 13
Major Shareholding Notification
2026
Feb 11
Regulatory Filings
2026
Feb 6
Director's Dealing
2026
Jan 20
Major Shareholding Notification
2026
Jan 16
Director's Dealing
2026
Jan 15
Director's Dealing
2026
Jan 12